{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:32:14Z","timestamp":1793212334067,"version":"4.5.0"},"reference-count":63,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:00:00Z","timestamp":1793145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:00:00Z","timestamp":1793145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"DOI":"10.1080\/13543784.2026.2754085","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:06:19Z","timestamp":1792674379000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Designing for success in early-phase hemophilia clinical trials: historical lessons and emerging principles for next-generation therapeutics"],"prefix":"10.1080","author":[{"given":"Johnny N.","family":"Mahlangu","sequence":"first","affiliation":[{"name":"University of the Witwatersrand","place":["Johannesburg, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,28]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-24"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0006098"},{"key":"e_1_3_5_5_1","unstructured":"World Federation of Hemophilia. Report on the annual global survey 2023. Montr\u00e9al QC: World Federation of Hemophilia; 2024 [cited 2026 Aug 1]. Available from: https:\/\/www1.wfh.org\/publications\/files\/pdf-2399.pdf"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106073442307"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13963"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199012273232604"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.9.2428.2428"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208024"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305074"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.6558"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209226"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616569"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00037-6"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027008"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216455"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00307-7"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027468"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1358"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-306647"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108046"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407309"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708538"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908490"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113708"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211644"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211075"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104205"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01751-0"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208486"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.10.010"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410597"},{"key":"e_1_3_5_37_1","unstructured":"US Food and Drug Administration. Expedited programs for regenerative medicine therapies for serious conditions: guidance for industry. Silver Spring (MD): FDA; 2019 [cited 2026 Oct 5]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/expedited-programs-regenerative-medicine-therapies-serious-conditions"},{"key":"e_1_3_5_38_1","unstructured":"US Food and Drug Administration. Human gene therapy for hemophilia: guidance for industry. Silver Spring (MD): FDA; 2020 [cited 2026 Oct 5]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-hemophilia"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.41"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3801"},{"key":"e_1_3_5_41_1","unstructured":"European Medicines Agency. Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. EMEA\/CHMP\/SWP\/28367\/07 Rev. 1. London: EMA; 2017 [cited 2026 Aug 5]. Available from: https:\/\/www.ema.europa.eu\/en\/strategies-identify-mitigate-risks-first-human-early-clinical-trials-investigational-medicinal-products-scientific-guideline"},{"key":"e_1_3_5_42_1","unstructured":"US Food and Drug Administration. Adaptive designs for clinical trials of drugs and biologics: guidance for industry. Silver Spring (MD): FDA; 2019 [cited 2026 Aug 5]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40814-018-0253-0"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13703"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.2196\/25071"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1159\/000071636"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-378935"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1598058"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13424"},{"key":"e_1_3_5_50_1","unstructured":"US Food and Drug Administration. Long term follow-up after administration of human gene therapy products: guidance for industry. Silver Spring (MD): FDA; 2020 [cited 2026 Aug 15]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/long-term-follow-after-administration-human-gene-therapy-products"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3389"},{"key":"e_1_3_5_52_1","unstructured":"International Conference on Harmonisation. Ich harmonised tripartite guideline: statistical principles for clinical trials E9. Geneva: ICH; 1998 [cited 2026 Aug 16]. Available from: https:\/\/www.ema.europa.eu\/en\/ich-e9-statistical-principles-clinical-trials-scientific-guideline"},{"key":"e_1_3_5_53_1","unstructured":"European Parliament and Council of the European Union. Regulation (EC) No 141\/2000 of 16 December 1999 on orphan medicinal products. Off J Eur Communities. 2000 [cited 2026 Aug 16];L18:1\u20135. Available from: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:32000R0141"},{"key":"e_1_3_5_54_1","unstructured":"International Council for Harmonisation. Ich harmonised guideline: general considerations for clinical studies E8(R1). Geneva: ICH; 2021 [cited 2026 Aug 16]. Available from: https:\/\/www.ema.europa.eu\/en\/ich-e8-r1-general-considerations-clinical-studies-scientific-guideline"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0561-9"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2548-6"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510062"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1351"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0701-3"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.01.011"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.05.005"},{"key":"e_1_3_5_62_1","unstructured":"US Food and Drug Administration. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. Silver Spring (MD): FDA; 2018\u20132023 [cited 2026 Aug 17]. Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical"},{"key":"e_1_3_5_63_1","unstructured":"Pfizer Inc. U.S. FDA approves Pfizer\u2019s BEQVEZ (fidanacogene elaparvovec-dzkt) a one-time gene therapy for adults with hemophilia B [press release]. New York (NY): Pfizer; 2024 Apr 26 [cited 2026 Aug 17]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-pfizers-beqveztm-fidanacogene-elaparvovec"},{"key":"e_1_3_5_64_1","unstructured":"Stansfield N. Pfizer jettisons FDA-approved hemophilia B gene therapy Beqvez. Cgtlive [Internet]. 2025 Feb 21 [cited 2026 Aug 15]. Available from: https:\/\/www.cgtlive.com\/view\/pfizer-jettisons-fda-approved-hemophilia-b-gene-therapy-beqvez"},{"key":"e_1_3_5_65_1","unstructured":"BioMarin Pharmaceutical Inc. BioMarin voluntarily withdraws ROCTAVIAN (valoctocogene roxaparvovec-rvox) from the market [company statement]. San Rafael (CA): BioMarin; 2026 Feb 23 [cited 2026 Oct 5]. Available from: https:\/\/www.biomarin.com\/news\/company-statements\/biomarin-voluntarily-withdraws-roctavian-from-the-market\/"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2754085","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543784.2026.2754085","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2754085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:36:43Z","timestamp":1793209003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2754085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,28]]},"references-count":63,"alternative-id":["10.1080\/13543784.2026.2754085"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2754085","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}